Carbinoxamine
Carbinoxamine is an antihistamine used to relieve symptoms of allergic rhinitis, other nasal allergy-type symptoms, allergic eye irritation, and allergic skin reactions such as hives.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 9 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
How we combine label and product data →
Carbinoxamine is an older antihistamine, on the U.S. market since about 1993 and available as a generic, that blocks histamine at H1 receptors to relieve nasal allergies (allergic rhinitis), itchy allergic eyes and hives, and it is usually a second choice behind newer non-drowsy antihistamines. Drowsiness is the trade-off most people notice, along with dry mouth, nose and throat from its drying (anticholinergic) effect, and some feel dizzy. It must never be given to a child under 2, because deaths have been reported in that age group. Skip alcohol, which deepens the drowsiness, and MAO inhibitors such as phenelzine, which intensify its drying effects.
Clinical pearls
- Take the tablets or oral solution on an empty stomach with water, and shake the extended-release suspension well before every dose.
- Measure liquid doses with a milliliter syringe or dosing cup, never a kitchen spoon, because small errors matter with this drug.
- Check labels on over-the-counter sleep aids and cold medicines, since many contain another sedating antihistamine like diphenhydramine that doubles the effect.
- The extended-release suspension contains a sulfite, so people with asthma or sulfite sensitivity should flag it before starting.
Patient information guide — a plain-language walkthrough of Carbinoxamine, written from its FDA label.
What Carbinoxamine is used for
▾
Carbinoxamine relieves symptoms of these allergy-related conditions:
- Seasonal and perennial allergic rhinitis
- Vasomotor rhinitis
- Allergic conjunctivitis due to inhalants and foods
- Mild, uncomplicated hives (urticaria) and angioedema
- Dermatographism
- Added therapy after anaphylaxis, alongside epinephrine, once the acute signs are controlled
- Lessening the severity of allergic reactions to blood or plasma
- Karbinal and the generic extended-release suspension are specified for adults and children 2 years and older
How Carbinoxamine works
▾
Carbinoxamine is an antihistamine. It competes with histamine at H1 receptors in the gut, blood vessels and airways, which reduces histamine's allergy effects.
It also has drying (anticholinergic) and sedating properties, which explains side effects like dry mouth and drowsiness.
Carbinoxamine dosage
▾
Carbinoxamine is taken by mouth. Tablets and oral solution (including Carbzah and RyVent) are taken on an empty stomach with water, several times a day. Karbinal and the generic extended-release suspension are taken every 12 hours.
- Doses are individualized to your symptoms and response.
- Shake the extended-release suspension well and measure with a milliliter device, not a household teaspoon.
- Follow your prescriber and label for dose and missed-dose advice.
Dosing details from the FDA-approved label
From the Carbinoxamine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults and Adolescents 12 years of age and older (extended-release oral suspension)
- 7.5 mL to 20 mL (6 mg to 16 mg) orally every 12 hours
- Individualize based on severity and response; start with lower doses and increase as needed and tolerated; measure with an accurate milliliter device, not a household teaspoon
- Pediatric patients 2 years to 3 years (extended-release oral suspension)
- 3.75 mL to 5 mL (3 mg to 4 mg) orally every 12 hours
- Approximately 0.2 mg/kg/day to 0.4 mg/kg/day for ages 2 to 11 years
- Pediatric patients 4 years to 5 years (extended-release oral suspension)
- 3.75 mL to 10 mL (3 mg to 8 mg) orally every 12 hours
- Approximately 0.2 mg/kg/day to 0.4 mg/kg/day for ages 2 to 11 years
- Pediatric patients 6 years to 11 years (extended-release oral suspension)
- 7.5 mL to 15 mL (6 mg to 12 mg) orally every 12 hours
- Approximately 0.2 mg/kg/day to 0.4 mg/kg/day for ages 2 to 11 years
- Usual Adult Dosage (tablets, 4 mg)
- 1 or 2 tablets (4 to 8 mg) 3 to 4 times daily
- Maximum: Well tolerated in adults in doses as high as 24 mg daily, in divided doses, over prolonged periods
- Take on an empty stomach with water; some patients respond to as little as 4 mg daily
- Usual Adult Dosage (oral solution)
- 1 or 2 teaspoonfuls (4 to 8 mg) 3 to 4 times daily
- Maximum: Well tolerated in adults in doses as high as 24 mg daily, in divided doses, over prolonged periods
- Take on an empty stomach with water
- Usual Child's Dosage, six to eleven years (tablets)
- ½ to 1 tablet (2 to 4 mg) 3 to 4 times daily
- Contraindicated in children younger than 2 years
- Usual Child's Dosage, six to eleven years (oral solution)
- ½ to 1 teaspoonful (2 to 4 mg) 3 to 4 times daily
- Approximately 0.2 to 0.4 mg/kg/day, divided into 3 to 4 doses
- Children 2 to 5 years of age (oral solution)
- Approximately 0.2 to 0.4 mg/kg/day, divided into 3 to 4 daily doses
- Generally ¼ to ½ teaspoonful (1 to 2 mg) 3 to 4 times daily
- Dosing should be based on weight whenever possible
- Usual Adult Dosage (RyVent tablet)
- 1 tablet (6 mg) 3 to 4 times daily
- Maximum: Well tolerated in adults in doses as high as 24 mg daily, in divided doses, over prolonged periods
- Take on an empty stomach with water
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Adults and Adolescents 12 years of age and older ( 2 .3): 7.5 mL to 20 mL (6 mg to 16 mg) orally every 12 hours Pediatric patients 2 years to 11 years of age (approximately 0.2 mg/kg/day to 0.4 mg/kg/day) ( 2 .4): 2 years to 3 years – 3.75 mL to 5 mL (3 mg to 4 mg) orally every 12 hours 4 years to 5 years – 3.75 mL to 10 mL (3 mg to 8 mg) orally every 12 hours 6 years to 11 years – 7.5 mL to 15 mL (6 mg to 12 mg) orally every 12 hours 2.1 General Administration Instructions The dosage of Karbinal ER should be individualized based on the severity of the condition and the response of the patient. Start with lower doses and increase as needed and tolerated. Administer Karbinal ER by the oral route only. Measure Karbinal ER with an accurate milliliter measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. A pharmacist can provide an appropriate measuring device and can provide instructions for measuring correct dose. Shake Karbinal ER well before use. 2.2 Recommended Dosage for Adults and Adolescents 12 years of age and older: Administer 7.5 mL to 20 mL (6 mg to 16 mg) orally every 12 hours 2.3 Recommended Dosage for Pediatric Patients 2 years to 11 years of age (approximately 0.2 mg/kg/day to 0.4 mg/kg/day) 2 years to 3 years: Administer 3.75 mL to 5 mL (3 mg to 4 mg) orally every 12 hours administered orally 4 years to 5 years: Administer 3.75 mL to 10 mL (3 mg to 8 mg) orally every 12 hours administered orally 6 years to 11 years: Administer 7.5 mL to 15 mL (6 mg to 12 mg) orally every 12 hours administered orally
2.1 General Administration Instructions The dosage of Karbinal ER should be individualized based on the severity of the condition and the response of the patient. Start with lower doses and increase as needed and tolerated. Administer Karbinal ER by the oral route only. Measure Karbinal ER with an accurate milliliter measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. A pharmacist can provide an appropriate measuring device and can provide instructions for measuring correct dose. Shake Karbinal ER well before use.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Carbinoxamine side effects
▾
Common side effects
- Sleepiness and sedation
- Dizziness
- Poor coordination
- Upset stomach (epigastric distress)
- Thickened bronchial secretions (mucus)
- Dry mouth, nose and throat
When to get medical help
- Get emergency help for signs of a severe allergic reaction, such as trouble breathing, wheezing, or swelling. The extended-release suspension contains a sulfite that can trigger this in sensitive people.
- Call your doctor about confusion, seizures, or a fast or pounding heartbeat.
- Call your doctor about difficulty urinating or inability to urinate.
- Seek urgent help for suspected overdose: hallucinations, convulsions, fixed dilated pupils, or flushing.
- Report unusual bruising or bleeding, or signs of infection, since blood problems have been reported.
Most side effects relate to sedation and the drying effect.
- Sedation and sleepiness
- Dizziness
- Disturbed coordination
- Epigastric (upper stomach) distress
- Thickened bronchial secretions
- Dry mouth, nose and throat
Seek help for severe allergic reactions, seizures, confusion, a fast heartbeat, or trouble urinating.
Carbinoxamine warnings and precautions
▾
- Children under 2: Deaths have been reported, so it is contraindicated.
- It may cause marked drowsiness and impair driving or machinery use.
- Use caution with glaucoma, an enlarged prostate, bladder or bowel blockage, stomach ulcer, thyroid, heart disease or high blood pressure.
- The extended-release suspension contains a sulfite that can cause serious allergic reactions, especially in people with asthma.
- Young children may become excited, and older adults are more sensitive to side effects.
Carbinoxamine interactions
▾
Carbinoxamine can add to or intensify the effects of other drugs.
- MAO inhibitors: do not combine, as they prolong and intensify the drying effects.
- Alcohol: adds to drowsiness.
- Sedatives, sleep aids and tranquilizers: additive CNS depression.
- Other antihistamines, barbiturates and tricyclic antidepressants: effects may increase.
Interactions listed in the FDA-approved label
From the Carbinoxamine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Monoamine oxidase inhibitors (MAOIs): MAOIs prolong and intensify the anticholinergic (drying) effects of antihistamines. Do not use carbinoxamine extended-release oral suspension in patients taking MAOIs.
- Alcohol: Additive adverse effects. Avoid concomitant use.
- Other CNS depressants (hypnotics, sedatives, tranquilizers, etc.): Additive adverse effects. Avoid concomitant use.
Read the label’s full interactions text
7 DRUG INTERACTIONS Do not use Carbinoxamine Maleate extended-release oral suspension in patients who are taking monoamine oxidase inhibitors (MAOIs), which prolong and intensify the anticholinergic (drying) effects of antihistamines. Avoid use of Carbinoxamine Maleate extended-release oral suspension with alcohol and other CNS depressants (hypnotics sedatives, tranquilizers, etc.) due to additive effects. Monoamine oxidase inhibitors (MAOIs): Prolong and intensify the anticholinergic (drying) effects. (4 and 7) Alcohol and CNS depressants (hypnotics sedatives, tranquilizers, etc.): Avoid concomitant use due to additive adverse effects. (7)
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Carbinoxamine
▾
- Do not use in children under 2 or if allergic to carbinoxamine or its ingredients.
- Do not use with MAO inhibitors.
- Tell your prescriber about glaucoma, prostate, bladder, stomach, thyroid, heart or blood pressure problems.
- Breastfeeding is not recommended during treatment.
- Ask your doctor about use in pregnancy.
- Older adults should start at lower doses and be watched for confusion and over-sedation.
Carbinoxamine overdose
▾
Too much can cause drowsiness or the opposite, stimulation, especially in children. Dry mouth, fixed dilated pupils, flushing, stomach symptoms, hallucinations, convulsions and death can occur, especially in infants and children. Get emergency help right away. Treatment is supportive and symptom-based.
What Carbinoxamine does in the body
▾
Carbinoxamine blocks histamine's action at H1 receptors in the gut, blood vessels and airways. It also has drying (anticholinergic) and sedating effects.
How your body processes Carbinoxamine
▾
Carbinoxamine is well absorbed from the gut. The liver extensively breaks it down, and inactive products leave in the urine within 24 hours. Its half-life is reported as 10 to 20 hours. In one study of the extended-release suspension, peak levels came between 1.5 and 5 hours.
How to store Carbinoxamine
▾
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15°C and 30°C (between 59°F and 86°F) . Dispense in a tight, light-resistant container with a child-resistant closure as defined in the official compendium.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Carbinoxamine: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Carbinoxamine — the kind of thing our pharmacy team would talk through with you at the counter.
What is carbinoxamine for?
▾
Will it make me sleepy?
▾
How should I take it?
▾
Can I give it to my young child?
▾
What should I avoid taking with it?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Carbinoxamine available over the counter?
▾
When was Carbinoxamine first available?
▾
Who makes Carbinoxamine?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Carbinoxamine on HelloPharmacist
Carbinoxamine forms and strengths (how it comes)
Carbinoxamine is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- RyVent tablets are used for symptomatic relief of allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild hives and angioedema, and dermatographism.
- RyVent should be taken on an empty stomach with water.
- RyVent is generally taken 3 to 4 times daily, with the dose individualized to your response.
- RyVent is not for children under 2 years of age.
Extended-release oral suspension
How this form is used
- Karbinal is indicated for adults and children 2 years and older for allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild hives and angioedema, and dermatographism.
- Karbinal is also used after anaphylaxis is controlled, alongside epinephrine, and for allergic reactions to blood or plasma.
- Karbinal is taken by mouth only, generally every 12 hours.
- Shake Karbinal well before each use.
- Measure Karbinal with an accurate milliliter device, not a household teaspoon.
- Karbinal contains sodium metabisulfite, a sulfite that can cause allergic-type reactions in sensitive people.
Oral solution
How this form is used
- Carbzah oral solution is used for symptomatic relief of allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild hives and angioedema, and dermatographism.
- Carbzah should be taken on an empty stomach with water.
- Carbzah is generally taken 3 to 4 times daily, with the dose adjusted to your response.
- Carbzah is not for children under 2 years of age.
Carbinoxamine on the U.S. market: products, makers and brands
How Carbinoxamine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
16 companies list 25 Carbinoxamine product records with the FDA, mostly as tablet, extended-release oral suspension, oral solution; the earliest marketing or approval year on record is 1993. Brand names on the directory include Karbinal, RyVent, Carbzah and 1 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (5) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Carbinoxamine is used (Medicaid data)
A general measure of how commonly Carbinoxamine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Carbinoxamine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Carbinoxamine prescribed? Of the 1,601 medications we measure, Carbinoxamine ranks #674 by Medicaid prescriptions — more than 58% of them.
Utilization by Carbinoxamine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
12 HR carbinoxamine maleate 0.8 MG/ML Extended Release Suspension Most dispensed
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1374770
carbinoxamine maleate 6 MG Oral Tablet
Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795581
carbinoxamine maleate 4 MG Oral Tablet
Summed across the 3 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1012904
carbinoxamine maleate 0.8 MG/ML Oral Solution
Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1010696
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Carbinoxamine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 11 of 18 listed Carbinoxamine NDCs with Medicaid activity.
Compare Carbinoxamine products
A representative set of FDA-listed product records for Carbinoxamine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Extended-release oral suspension | ||||
| 4 mg/5 mL | Oral | Aytu Therapeutics, LLC × 3 listings | NDA | View NDC → |
| 4 mg/5 mL | Oral | Neos Therapeutics, LP | NDA AUTHORIZED GENERIC | View NDC → |
| 💊Oral solution | ||||
| 4 mg/5 mL | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| 4 mg/5 mL | Oral | Genus Lifesciences Inc. × 2 listings | ANDA | View NDC → |
| 4 mg/5 mL | Oral | IPG Pharmaceuticals, inc. | ANDA | View NDC → |
| 💊Tablet | ||||
| 4 mg | Oral | Biocomp Pharma, Inc. × 2 listings | ANDA | View NDC → |
| 6 mg | Oral | BluCrest Pharmaceuticals, LLC | ANDA | View NDC → |
| 4 mg | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| 6 mg | Oral | Carwin Pharmaceutical Associates, LLC × 2 listings | ANDA | View NDC → |
| 6 mg | Oral | Foxland Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 4 mg | Oral | Genus Lifesciences Inc. × 2 listings | ANDA | View NDC → |
| 6 mg | Oral | Leading Pharma, LLC | ANDA | View NDC → |
| 6 mg | Oral | Tripoint Therapeutics, Llc | ANDA | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Kongo Chemical Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | MSN Pharmachem Private Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | R.L.Fine Chem Private Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Symed Labs Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Viyash Scientific Limited | BULK INGREDIENT | View NDC → |
Showing 25 of 25 products — FDA National Drug Code Directory. See every product, package size and price: browse all 25 Carbinoxamine NDCs →
Carbinoxamine side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Carbinoxamine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Carbinoxamine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Carbinoxamine FDA approval history
How Carbinoxamine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Carbinoxamine recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Carbinoxamine recalls since July 2021.
✅No Carbinoxamine recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 20220 3 dose forms · 4 strengths
-
Dose form (SCDF) Extended Release Suspension RxCUI 582331In current FDA listingsClinical drug / strength (SCD) 12 HR carbinoxamine maleate 0.8 MG/MLRxCUI 1374770 -
Dose form (SCDF) Oral Solution RxCUI 371275In current FDA listingsClinical drug / strength (SCD) maleate 0.8 MG/MLRxCUI 1010696 -
Dose form (SCDF) Oral Tablet RxCUI 371277In current FDA listings
Look up RxCUI 20220 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Carbinoxamine supply and shortage status
Whether Carbinoxamine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Carbinoxamine brand names
Carbinoxamine is sold under 4 brand names in the FDA directory — Karbinal, RyVent, Carbzah, Karbinal ER. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Carbinoxamine: manufacturers and labelers
16 companies list Carbinoxamine products with the FDA. By number of product records, the largest are Genus Lifesciences Inc., Aytu Therapeutics, LLC, Biocomp Pharma, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Carbinoxamine drug class (RxNorm)
Carbinoxamine belongs to the Histamine-1 Receptor Antagonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Carbinoxamine page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Aytu Therapeutics, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →